NSPR - InspireMD, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
1.4900
-1.1100 (-42.69%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.6000
Open0.0000
Bid0.0000 x 1800
Ask1.4900 x 2900
Day's Range0.0000 - 0.0000
52 Week Range
Volume0
Avg. Volume183,371
Market Cap2.083M
Beta (3Y Monthly)3.52
PE Ratio (TTM)N/A
EPS (TTM)-9.9060
Earnings DateNov 4, 2019 - Nov 8, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
Trade prices are not sourced from all markets
  • GlobeNewswire

    InspireMD, Inc. Announces Pricing of $5 Million Underwritten Public Offering

    InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, today announced the pricing of an underwritten public offering of 2,777,777 units at a price to the public of $1.80 per unit. InspireMD expects to receive aggregate gross proceeds of approximately $5 million from the offering, assuming no exercise of the underwriter’s option to purchase additional securities. Each unit contains one share of common stock (or common stock equivalent) and one Series E warrant to purchase one share of common stock at an exercise price of $1.80 per share.

  • GlobeNewswire

    InspireMD Provides Business Update

    TEL AVIV, Israel, Sept. 09, 2019 -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by.

  • GlobeNewswire

    InspireMD to Present at the HC Wainwright 21st Annual Global Investment Conference

    TEL AVIV, Israel, Sept. 09, 2019 -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by.

  • Thomson Reuters StreetEvents

    Edited Transcript of NSPR earnings conference call or presentation 6-Aug-19 12:00pm GMT

    Q2 2019 InspireMD Inc Earnings Call

  • 4 Defensible Healthcare Stocks Gaining While the Market Falls
    TipRanks

    4 Defensible Healthcare Stocks Gaining While the Market Falls

    With the latest escalation of the U.S.-China trade war on August 23, investors are looking for defensible stocks that still represent compelling investments in a volatile market. According to research from Goldman Sachs, these investments can be found within the healthcare sector. “Funds have steadily reduced the share of market cap owned among the stocks most exposed to US-China trade conflict, such as semiconductors,” Goldman strategist Ben Snider wrote in a note to clients. He added that even with the risk of health care regulation that attracted attention from investors earlier in the year, healthcare stocks still present a strong opportunity given the economic landscape. We looked at 4 of the top August 23 gainers in this sector to find the most compelling investments. Let’s dive in. Endologix, Inc. (ELGX)Endologix develops innovative and minimally invasive technologies for aortic disorders including abdominal aortic aneurysms (AAA). With shares gaining 4% on August 23, some analysts argue this healthcare stock is just getting started. The jump comes one day after ELGX canceled its agreement with Piper Jaffray for the at-the-market sale of up to $25 million of its common stock. While this would have given the company additional capital, several recent positive developments suggest ELGX is still on track for long-term growth.On August 8, the company announced its agreement to give Boston Scientific (BSX) exclusive rights to distribute its Endologix products in China. Not to mention that same day it received Investigational Device Exemption (IDE) approval from the FDA to begin a new pivotal study evaluating the safety and effectiveness of the Nellix Chimney EndoVascular Aneurysm Sealing System (ChEVAS) for endovascular treatment of complex AAA.Based on all of the above factors, BTIG analyst Sean Lavin reiterated his Buy rating and $12 price target on August 12. The 3.5-star analyst believes share prices could soar 118% over the next twelve months.All in all, the Street is cautiously optimistic on this healthcare stock. ELGX has a ‘Moderate Buy’ analyst consensus and an $8 average price target, suggesting 51% upside. T2 Biosystems Inc. (TTOO) This healthcare stock develops and commercializes medical diagnostic products for the detection of additional species and antibiotic resistance markers of sepsis pathogens as well as tests for Lyme disease. In the last five days, shares are up 49% with shares gaining over 3% on August 23 alone.Shares got a boost shortly after T2 announced that it had entered into an exclusive agreement that will allow the company to introduce its rapid diagnostic technologies, including the T2Bacteria and T2Candida Panels, and enter into new markets in Australia, Fiji and New Zealand. These countries have approximately 1,150 hospitals that could benefit from T2’s products. It doesn’t hurt that its T2Bacteria Panel received approval for a New Technology Add-on Payment (NTAP) from the Centers for Medicare & Medicaid Services (CMS) on August 6, making it the first and only in-vitro diagnostic test to ever receive approval for NTAP.“We view this development as an unexpected victory that sort of came out of left field (as management had not indicated plans to pursue this add- on payment). While management has indicated that pricing (cost) of their panels has historically not been a meaningful barrier to driving adoption, we think that anything sold into a hospital is scrutinized from a cost and ROI perspective, even if it is clear that the technology has clinical utility for the patient,” noted Canaccord Genuity analyst Mark Massaro. As a result, the five-star analyst reiterated his Buy rating and $2.50 price target on August 6. He believes shares could soar 110% over the next twelve months. Wall Street takes a less bullish stance on TTOO. It has a ‘Hold’ analyst consensus and a $1 average price target, indicating 22% upside potential. InspireMD Inc. (NSPR)The vascular procedure technology company saw shares jump almost 2% on August 23 as well as a 32% gain in the last five days, with some analysts saying there’s no sign of a slowdown on the horizon.The upward move follows the announcement of its planned public offering of units, each consisting of one common share and one Series E warrant. Investors have expressed concern regarding a letter from the NYSE American it received on August 7, 2019. It indicated that InspireMD does not meet a certain listing standards due to the fact that the company had reported stockholders’ equity of less than $6 million as of June 30, 2019 and had net losses in its five most recent fiscal years. That being said, analyst Vernon Bernardino argues that the public offering is a move in the right direction. As a result, he reiterated his Buy rating and $5 price target. The H.C. Wainwright analyst believes shares could surge 71% in the next twelve months. NSPR boasts a ‘Moderate Buy’ analyst consensus and a $5 average price target, implying 71% upside potential. Zymeworks Inc. (ZYME)This biotech company develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. With shares up over 1% on August 23, some analysts believe now is the time to buy.Investors were impressed when ZYME posted strong Q2 earnings results on August 2. While EPS fell short of the consensus estimate by one cent, it was able to pull off a revenue beat.These results were boosted by a $7.5 million milestone payment from its partner Celgene (CELG) on July 16. The payment was triggered when CELG announced that it selected a lead oncology candidate and exercised its option for commercialization rights under their 2014 Azymetric agreement.After the news of the milestone payment broke, Deutsche Bank analyst Kostantinos Aprilakis told investors that the stock price represents a buying opportunity. This played into the analyst’s decision to initiate coverage with a Buy and set a $34 price target. He thinks shares could gain 36% in the next twelve months.In general, the Street takes a slightly more cautious stance on ZYME. It has a ‘Moderate Buy’ analyst consensus and a $29 average price target, suggesting 14% upside potential. Find analysts’ favorite stocks with the Top Analysts’ Stocks tool

  • GlobeNewswire

    InspireMD Announces Notification of NYSE AMERICAN Listing Deficiency

    InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that it has received a letter from the NYSE American on August 7, 2019, indicating that InspireMD does not meet a certain NYSE American LLC (the “NYSE American”) continued listing standard as set forth in Part 10, Section 1003(a)(iii) of the Company Guide of the NYSE American, due to the fact the Company had reported stockholders’ equity of less than $6 million as of June 30, 2019, and had net losses in its five most recent fiscal years ended December 31, 2018. The Exchange's notice has no immediate effect on the listing of the Company's common stock on the Exchange.

  • GlobeNewswire

    InspireMD Announces Second Quarter 2019 Financial Results

    U.S. Investigational Device Exemption (IDE) application submitted to FDA Company to host investor conference call today, August 6, at 8:00am ET TEL AVIV, Israel, Aug. 06,.

  • GlobeNewswire

    InspireMD to Report Second Quarter 2019 Financial Results and Provide Business Update on Tuesday, August 6

    TEL AVIV, Israel, July 30, 2019 -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the.

  • InspireMD (NSPR) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
    Zacks

    InspireMD (NSPR) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

    InspireMD (NSPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Do Institutions Own InspireMD, Inc. (NYSEMKT:NSPR) Shares?
    Simply Wall St.

    Do Institutions Own InspireMD, Inc. (NYSEMKT:NSPR) Shares?

    A look at the shareholders of InspireMD, Inc. (NYSEMKT:NSPR) can tell us which group is most powerful. Institutions...

  • Thomson Reuters StreetEvents

    Edited Transcript of NSPR earnings conference call or presentation 14-May-19 12:00pm GMT

    Q1 2019 InspireMD Inc Earnings Call

  • GlobeNewswire

    InspireMD Announces First Quarter 2019 Financial Results

    On-Track to Submit U.S. IDE expected in Mid-2019 Company to Host Investor Conference Call at 8:00am ET TEL AVIV, Israel, May 14, 2019 -- InspireMD, Inc. (NYSE American:.

  • GlobeNewswire

    InspireMD to Report First Quarter 2019 Financial Results and Provide Business Update on Tuesday, May 14

    TEL AVIV, Israel, May 07, 2019 -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the.

  • GlobeNewswire

    InspireMD, Inc. Announces Pricing of $2.4 Million Public Offering of Common Stock

    InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced the pricing of its previously announced underwritten public offering of 486,957 shares of its common stock at a price to the public of $5.00 per share. The offering is expected to close on or about April 8, 2019, subject to customary closing conditions.  InspireMD also granted the underwriter a 30-day option to purchase an additional 73,043 shares of its common stock. H.C. Wainwright & Co. is acting as the sole book-running manager for the offering.

  • GlobeNewswire

    InspireMD, Inc. Announces Proposed Public Offering of Common Stock

    InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. InspireMD also expects to grant the underwriter a 30-day option to purchase additional shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

  • ACCESSWIRE

    A Reverse Split and Key Demand Drivers for InspireMD's Proprietary Technology

    NEW YORK, NY / ACCESSWIRE / April 1, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuinga comprehensive report on InspireMD, Inc. (NSPR), a biotechnology company that has developed a portfolio of medical device assets using a proprietary technology called MicroNet. CGuard EPS is the company's lead product, and it's a highly differentiated, minimally invasive treatment for carotid artery disease designed around its proprietary and elegantly simple MicroNet technology to dramatically reduce or even eliminate the incidence of stroke following carotid artery procedures.

  • GlobeNewswire

    InspireMD Announces 1-for-50 Reverse Stock Split

    InspireMD, Inc. (NYSE American: NSPR, NSPR.WS, NSPR.WSB), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that its Board of Directors has approved a one-for-fifty reverse stock split of its common stock that is scheduled to become effective after trading closes on March 29, 2019. Beginning on April 1, 2019, the Company’s common stock will trade on the NYSE American on a split adjusted basis under a new CUSIP number 45779A 853. The Company’s common stock will continue to trade on the NYSE American under the symbol “NSPR.” As previously disclosed, at the InspireMD Annual Meeting of Stockholders held on March 21, 2019, the Company’s stockholders approved a proposal authorizing the Company’s Board of Directors to effect a reverse stock split at a ratio in the range of one-for-twenty-five and one-for-fifty in order to help regain compliance with the NYSE American’s minimum price requirements.

  • GlobeNewswire

    InspireMD Provides Amended Disclosure

    InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today provided an amended disclosure to conform to the Company’s Form 10-K that was filed with the SEC on February 19, 2019. As disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, which was filed on February 19, 2019 with the Securities and Exchange Commission, the audited financial statements contained a going concern qualification paragraph in the audit opinion from its independent registered public accounting firm.  See further discussion in Note 1 to the Company’s consolidated financial statements included in the Company’s Annual Report on Form 10-K. This announcement is made pursuant to NYSE American Company Guide Section 610(b), which requires public announcement of the receipt of an audit opinion containing a going concern paragraph.

  • GlobeNewswire

    InspireMD Announces Fourth Quarter 2018 Financial Results

    2018 CGuard™ EPS annual sales increased 55% compared to 2017 On-Track to Submit U.S. IDE in Mid-2019 Company to Host Investor Conference Call at 8:00am ET TEL AVIV, Israel,.

  • GlobeNewswire

    InspireMD to Report Fourth Quarter and Fiscal 2018 Financial Results and Provide Business Update on Tuesday, February 19

    TEL AVIV, Israel, Feb. 07, 2019 -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the.

  • GlobeNewswire

    InspireMD Announces Presentation of Interim Data from Investigator-Initiated Study Comparing CGuard™ EPS with a Conventional Open-Cell Carotid Stent

    CGuard™ EPS shows encouraging interim results verses a conventional carotid stent in absence of any adverse clinical events in the CGuard™ arm Data presented at the LINC 2019.

  • GlobeNewswire

    InspireMD Announces Two Successful Live Clinical Case Transmissions Featuring CGuard™ EPS at the Leipzig Interventional Course (LINC) 2019

    InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that two successful live cases featuring CGuard™ EPS were presented at LINC 2019, which is being held January 21 – 23 in Leipzig, Germany. “The live demonstrations of CGuard™ EPS at this year’s LINC conference, a major international interventional conference covering the latest innovations in vascular medicine, allowed attending physicians to see first-hand the simplicity of the CGuard EPS procedure as conducted by world renowned interventional cardiologists and angiologists,” said Dr. James Barry, President and Chief Executive Officer of InspireMD.

  • GlobeNewswire

    InspireMD Announces Results from Initial Clinical Study of The CGuard™ Embolic Prevention System (EPS) with SmartFit™ Technology

    InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced details of a new investigator-initiated trial entitled, “Initial Clinical Study of the New CGuard™ EPS MicroNet® Covered Carotid Stent: ‘One Size Fits All,’” at the Leipzig Interventional Course (LINC), which is being held January 22-25, 2019 in Leipzig, Germany. “One of the keys to successfully treating patients with carotid artery disease is to employ a device that is optimally sized,” commented Prof. Wissgott.

  • GlobeNewswire

    InspireMD’s CGuard™ Embolic Prevention System to be Prominently Featured in Live Case Transmissions at LINC, 22nd to the 25th January 2019, in Leipzig, Germany

    TEL AVIV, Israel, Jan. 18, 2019 -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,.

  • GlobeNewswire

    InspireMD Announces the Distribution of CGuard™ Embolic Prevention System in South Africa

    InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that its novel CGuard EPS will be distributed by its local distribution partner, Torque Medical of Roodepoort, Johannesburg. Craig Goodburn, Managing Member of Torque Medical, commented, “We are extremely pleased with the opportunity to offer CGuard EPS in the South African market.